Urokinase system expression in gastric carcinoma: Prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens

Cancer

Volumn 106, Issue 5, 2006, Pages 1026-1035

  Beyer, Bianca C M ^a   Heiss, Markus Maria ^b   Simon, Erich H ^c   Gruetzner, Klaus Uwe ^a   Babic, Rudolf ^d   Jauch, Karl Walter ^a   Schildberg, Friedrich Wilhelm ^a   Allgayer, Heike ^c,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Institute of Pathology and Cytology   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Gastric carcinoma; Helicobacter pylori; Intestinal metaplasia; Minimal residual disease; Preoperative biopsies; Prognosis; Urokinase type plasminogen activator system

Indexed keywords

CYTOKERATIN 18; PLASMINOGEN ACTIVATOR INHIBITOR 1; UREASE; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH BIOPSY; STOMACH CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HELICOBACTER INFECTIONS; HUMANS; INTESTINES; LYMPHATIC METASTASIS; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; RISK FACTORS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 33644522032     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21682     Document Type: Article

References (31)

1. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993;15:105-111.
2. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998;94:353-362.
3. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. J Biol Chem. 1991;266:12752-12758.
4. Conese M, Olson D, Blasi FAD. Protease nexin-1-urokinase complexes are internalized through a mechanism that requires both urokinase-receptor and α2-macroglobulin-receptor. J Biol Chem. 1994;269:17886-17892.
5. 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995;181:1381-1390.
6. Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995;60:501-506.
7. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven JH, Lamers CB. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut. 1993;34:80-85.
8. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991;51:4067-4071.
9. Heiss MM, Babic R, Allgayer H, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol. 1995;13:2084-2093.
10. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990;50:6827-6829.
11. Jaenicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat. 1993;24:195-208.
12. Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 1994;54:120-123.
13. Mulcahy HE, Duffy MJ, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 1994;344:583-584.
14. Ganesh S, Sier CFM, Heerding MM, et al. Urokinase receptor and colorectal cancer survival. Lancet. 1994;344:401-402.
15. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54:2900-2907.
16. Heiss MM, Allgayer H, Gruetzner KU, et al. Clinical value of an extended biological staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg. 1997;226:736-745.
17. Allgayer H, Heiss MM, Riesenberg R, Babic R, Jauch KW, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R)-a potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 1997;57:1394-1399.
18. Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor-expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995;1:1035-1039.
19. Heiss MM, Simon EH, Beyer BCM, et al. Minimal residual disease in gastric cancer: first evidence of an independent prognostic relevance of urokinase receptor gene expression by disseminated tumor cells in a large series of patients. J Clin Oncol. 2002;20:2005-2016.
20. Hermanek P, Maruyama K, Sobin LH. Stomach carcinoma. In Hermanek P, Gospodarowicz MK, Henson DE, editors. Prognostic factors in cancer. Berlin: Springer, 1995:47-64.
21. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
22. Borrmann R. Geschwuelste des Magens. In: Henke FU, Lubarsch O, editors. Handbuch der speziellen pathologischen anatomie und histologie, vol VI/1. Berlin: Springer, 1926:161-173.
23. Harbeck N, Kates R, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n = 3424). Cancer Res. 2002;62:4617-1622.
24. MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001;12:863-879.
25. De Bruin PA, Verspaget HW, Griffioen G, Verheijen JH, Dooijewaar Lamers CB. Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens. Br J Cancer. 1989;60:397-400.
26. Genta RM. The gastritis connection: prevention and early detection of gastric neoplasms. J Clin Gastroenterol. 2003;36:S44-S49.
27. Herszenyi L, Plebani M, Carraro P, et al. Impaired fibrinolysis and increased protease levels in gastric duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol. 1997;92:843-847.
28. Gotz JM, Vergouwe Y, Verspaget HW, et al. Gastric mucosal plasminogen activators in Helicobacter pylori infection. Dig Dis Sci. 1996;41:1577-1582.
29. Ljungh A. Helicobacter pylori interactions with plasminogen. Methods. 2000;21:151-157.
30. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004;53:1217-1219.
31. Conchillo JM, Houben G, de Bruine A, Stockbrugger R. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev. 2001;10:307-312.